The Gut Microbe That Makes Its Own Inflammatory Weapon During Crohn’s Flares

Most gut bacteria are bystanders in inflammatory bowel disease. Ruminococcus gnavus may not be. New research published in PNAS has identified a specific polysaccharide that this mucus-dwelling microbe synthesizes and secretes, one capable of triggering a potent inflammatory response in immune cells. The finding is emerging-stage science, but it offers the first molecular explanation for why R. gnavus blooms so reliably during Crohn's disease (CD) flares.

Glucorhamnan polysaccharide from R. gnavus triggers TNFα in dendritic cells

Using bioactivity-guided fractionation of R. gnavus culture fluid, researchers isolated a novel polysaccharide they named glucorhamnan and screened it for inflammatory activity. The molecule induced robust TNFα secretion from mouse bone marrow-derived dendritic cells, and that response depended on Toll-like Receptor 4 (TLR4): cells from tlr4-knockout mice showed no response, while cells from tlr2-knockout mice responded normally. TLR4 is the same receptor that detects bacterial lipopolysaccharide, meaning the immune system is treating this sugar polymer as a genuine danger signal.

Chemical analysis pinned down the structure. Gas chromatography-mass spectrometry found a glucose-to-rhamnose ratio of roughly 1:4, and NMR studies identified five distinct anomeric signals corresponding to a repeating unit of five sugars. The backbone consists of 1,3- and 1,2-linked rhamnose residues; short sidechains carry two glucose residues, one 1,6-linked and one terminal. The intact molecule weighs roughly 9 kilodaltons. In terms of raw potency, the glucorhamnan was comparable to yeast mannan, a well-characterized inflammatory polysaccharide used as a benchmark in immune studies.

Why R. gnavus blooms matter for Crohn's disease patients

Crohn's disease affects millions of people globally and is incurable; treatment currently centers on managing symptoms, often with anti-TNFα antibody therapies. That makes a bacterium that independently produces a TNFα-inducing molecule a clinically relevant finding.

In healthy guts, R. gnavus typically makes up less than 0.1 percent of the total microbiota. During severe CD flares, that fraction can reach 69 percent. The blooms are transient: as patients enter remission, R. gnavus returns to background levels. This on-off pattern aligns suspiciously well with flare-remission cycles, and glucorhamnan production could be part of the reason. The bacterium colonizes the intestinal mucosal surface by foraging sialic acid from mucin glycans, which may already compromise the gut barrier before the polysaccharide even reaches immune cells. Elevated R. gnavus has also been linked to spondyloarthritis, infant eczema, and pouchitis, suggesting that glucorhamnan-driven inflammation may extend beyond the gut.

How bioactivity-guided fractionation isolated the inflammatory molecule

Identifying which of the many molecules in a bacterial culture is responsible for a specific biological effect is genuinely hard work. The team cultured R. gnavus in defined media to avoid polysaccharide contamination from commercial growth broths, then systematically fractionated the culture supernatant while testing each fraction for TNFα-inducing activity via ELISA. This bioactivity-guided approach allowed them to home in on the glucorhamnan without presupposing its chemical identity.

To confirm the polysaccharide nature of the molecule, they subjected it to proteinase, nuclease, lysozyme, and heat treatments; none abolished its activity. This ruled out proteins, nucleic acids, and common bacterial surface components as the active factor. Bioinformatics then identified a putative biosynthetic gene cluster spanning genes RUMGNA_03512 to RUMGNA_03534, which encodes all four enzymes needed for rhamnose biosynthesis plus five glycosyltransferases. Quantitative PCR confirmed that key genes in this cluster are actively expressed during R. gnavus growth. Two genes encoding LytR/CpsA/Psr-like proteins suggest the glucorhamnan is covalently anchored to peptidoglycan, making it a genuine cell-wall component rather than a freely secreted exopolysaccharide.

Open questions about glucorhamnan structure and strain diversity

Several important gaps remain. Genetic manipulation of R. gnavus is not yet possible, so the researchers could not directly knock out the putative biosynthetic cluster to confirm its role. That means the gene-to-molecule connection, while strongly supported by bioinformatics and expression data, is still inferential.

The structural picture also has loose ends. The precise connectivity between a poly-1,3-phosphoglycerol modification and the glucorhamnan backbone has not been fully resolved, and the degree to which glucorhamnan structure varies across R. gnavus strains is unknown. That last point matters considerably: R. gnavus shows up to 74 percent genomic variability across strains, which may explain why some studies find it harmful and others do not. Strains lacking the glucorhamnan gene cluster might be metabolically similar but immunologically inert.

What glucorhamnan research could unlock for IBD treatment

If glucorhamnan production can be confirmed as a driver of CD flares rather than just a correlate, several therapeutic angles open up. Blocking TLR4 activation by the polysaccharide, targeting the biosynthetic gene cluster directly, or developing diagnostics based on glucorhamnan levels in stool are all plausible follow-on directions. The gene cluster is conserved across many clinical R. gnavus isolates, which supports its relevance beyond a single lab strain.

Longer-term, the bacterium's unique sialic acid metabolism pathway is already being explored as a basis for strain-specific biomarkers and next-generation prebiotics designed to suppress harmful R. gnavus variants while leaving beneficial strains intact. Understanding the glucorhamnan's role in TLR4-driven inflammation would sharpen those efforts considerably.

For now, the study reframes R. gnavus from a passive marker of gut dysbiosis into a microbe with a specific molecular tool for provoking immune activation. That distinction matters for patients and researchers alike, even if the full clinical implications are still being worked out.

Evidence rating

EMERGING — 78/100

Caveats:

• Inflammatory effects were demonstrated in mouse immune cells, not directly in human patients.
• Genetic knockout of the proposed biosynthetic gene cluster has not yet been achieved, so the causal role of that cluster remains unconfirmed.
• The study does not establish whether glucorhamnan levels in vivo are sufficient to drive the inflammation observed clinically.
• Funding source was not disclosed by the authors.

Mechanistic laboratory study using bioactivity-guided fractionation, chemical characterization (GC-MS, NMR), and mouse bone marrow-derived dendritic cell assays. Demonstrates a plausible step-by-step causal chain from a named R. gnavus polysaccharide to TLR4-dependent TNFα induction, but immune activity was measured in murine cells rather than human subjects, and genetic confirmation of the proposed biosynthetic gene cluster is not yet available. The findings are consistent with epidemiological associations reported in prior Crohn's disease literature but have not been independently replicated at the mechanistic level.